Final data from long-term study indicate clearly positive effects in the form of fewer and shorter seizures
Panion’s epilepsy product in development for dogs is based on CombiGene’s candidate drug, for which an important study report has just been released.Final data from CombiGene’s preclinical proof-of-concept-study (the long-term study) show that CombiGene’s candidate drug, CG01, has clear antiepileptic effects. The study has demonstrated that CG01 reduces the frequency and duration of epileptic seizures in treatment-responsive animals. A couple of the animals were completely free of seizures after being treated. No side effects have been observedin the study. Panion’s CEO Anja Holm